BNP Paribas Financial Markets Has $543,000 Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

BNP Paribas Financial Markets increased its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 37.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,758 shares of the medical device company’s stock after buying an additional 9,456 shares during the period. BNP Paribas Financial Markets owned 0.09% of Orthofix Medical worth $543,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of Orthofix Medical by 6.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,772 shares of the medical device company’s stock valued at $1,906,000 after acquiring an additional 9,118 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Orthofix Medical by 25.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company’s stock valued at $125,000 after purchasing an additional 1,919 shares during the last quarter. nVerses Capital LLC bought a new position in Orthofix Medical during the second quarter worth about $27,000. Victory Capital Management Inc. acquired a new position in Orthofix Medical during the second quarter worth approximately $832,000. Finally, Arizona State Retirement System bought a new stake in Orthofix Medical in the second quarter valued at approximately $139,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OFIX has been the subject of several research analyst reports. Roth Mkm reiterated a “buy” rating and set a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Orthofix Medical Trading Down 0.7 %

Shares of OFIX stock opened at $17.96 on Friday. Orthofix Medical Inc. has a 12-month low of $11.86 and a 12-month high of $20.73. The company has a market capitalization of $686.32 million, a PE ratio of -5.74 and a beta of 1.09. The firm has a 50 day moving average price of $17.55 and a two-hundred day moving average price of $16.06. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.